DexCom, Inc.

NasdaqGS:DXCM Rapport sur les actions

Capitalisation boursière : US$29.9b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

DexCom Résultats passés

Passé contrôle des critères 5/6

DexCom a connu une croissance annuelle moyenne de ses bénéfices de 28.5%, tandis que le secteur Medical Equipment a vu ses bénéfices augmenter de en hausse à 11.2% par an. Les revenus ont augmenté de en hausse à un taux moyen de 21.3% par an. Le rendement des capitaux propres de DexCom est 27.4% et ses marges nettes sont de 16.9%.

Informations clés

28.5%

Taux de croissance des bénéfices

28.0%

Taux de croissance du BPA

Medical Equipment Croissance de l'industrie8.9%
Taux de croissance des recettes21.3%
Rendement des fonds propres27.4%
Marge nette16.9%
Dernière mise à jour des bénéfices30 Jun 2024

Mises à jour récentes des performances passées

Recent updates

DexCom Q2 Earnings: Traditional Market Overreaction

Aug 07

Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?

Jul 26
Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?

DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures

Jul 26

Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E

Jul 12
Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E

DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact

Jul 03

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Jun 28
DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Jun 03
Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Dexcom: Positive Catalysts Ahead To Support Growth

May 13

If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity

May 07
If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity

DexCom: Attractive Discount After Strong Earnings Results

May 06

Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

Apr 25
Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

Apr 12
Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

DexCom Is Pricey For A Reason - Its Growth Story Reflects That

Apr 11

Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Mar 29
Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Mar 04
Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

DexCom: A Wealth Compounder In Healthcare

Feb 14

DexCom: Stelo Stellar Outlook

Jan 17

DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

Jan 15
DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

Jan 01
DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Dec 18
DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Dec 05
A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?

Nov 21
At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?

DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital

Sep 28
DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital

DexCom (NASDAQ:DXCM) Could Easily Take On More Debt

Sep 13
DexCom (NASDAQ:DXCM) Could Easily Take On More Debt

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Aug 29
Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Aug 14
Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet

Jun 05
DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet

There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

May 16
There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

Mar 21
Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

Mar 03
These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

Feb 13
DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly

Nov 25
DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly

Returns Are Gaining Momentum At DexCom (NASDAQ:DXCM)

Oct 21
Returns Are Gaining Momentum At DexCom (NASDAQ:DXCM)

Dexcom launches G7 glucose monitoring system in parts of Europe, Asia

Oct 04

What Is DexCom, Inc.'s (NASDAQ:DXCM) Share Price Doing?

Sep 24
What Is DexCom, Inc.'s (NASDAQ:DXCM) Share Price Doing?

Ventilation des recettes et des dépenses

Comment DexCom gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

NasdaqGS:DXCM Recettes, dépenses et bénéfices (USD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 243,9356671,242545
31 Mar 243,8026391,208528
31 Dec 233,6225421,185506
30 Sep 233,4033771,174486
30 Jun 233,1983581,135465
31 Mar 233,0232931,085467
31 Dec 222,9103411,008484
30 Sep 222,793244936605
30 Jun 222,673230900623
31 Mar 222,572258837631
31 Dec 212,449217811604
30 Sep 212,319577749487
30 Jun 212,170562709445
31 Mar 212,027530660396
31 Dec 201,927550618360
30 Sep 201,821231574320
30 Jun 201,716205539299
31 Mar 201,601148541288
31 Dec 191,476101516274
30 Sep 191,351-171499252
30 Jun 191,222-170479236
31 Mar 191,128-130452214
31 Dec 181,032-127433417
30 Sep 1891543414191
30 Jun 18833-5393184
31 Mar 18761-33368182
31 Dec 17719-50349185
30 Sep 17669-48336180
30 Jun 17633-65327181
31 Mar 17599-88311172
31 Dec 16573-66286156
30 Sep 16533-57268141
30 Jun 16490-80245125
31 Mar 16445-64221113
31 Dec 15402-58198101
30 Sep 15356-5817394
30 Jun 15319-2015585
31 Mar 15285-2314076
31 Dec 14259-2212869
30 Sep 14227-2611660
30 Jun 14201-2710452
31 Mar 14178-319447
31 Dec 13160-308442
30 Sep 13142-367839

Des revenus de qualité: DXCM a des bénéfices de haute qualité.

Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de DXCM (16.9%) sont supérieures à celles de l'année dernière (11.2%).


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: DXCM est devenue rentable au cours des 5 dernières années, augmentant ses bénéfices de 28.5% par an.

Accélération de la croissance: La croissance des bénéfices de DXCM au cours de l'année écoulée ( 86.5% ) dépasse sa moyenne sur 5 ans ( 28.5% par an).

Bénéfices par rapport au secteur d'activité: La croissance des bénéfices DXCM au cours de l'année écoulée ( 86.5% ) a dépassé celle du secteur Medical Equipment 5.5%.


Rendement des fonds propres

ROE élevé: Bien que le retour sur capitaux propres ( 27.4% ) de DXCM soit élevé, cette mesure est faussée en raison de son niveau d'endettement élevé.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé